US FDA seeks failed bioequivalence studies for generics
This article was originally published in Scrip
Executive Summary
The US FDAwill soon require ANDA applicants to submit data from all bioequivalence studies conducted on a generic drug product formulation filed for approval, rather than just those that successfully demonstrate bioequivalence to the reference listed drug.